CY1120169T1 - Παραγωγο αμιδιου και φαρμακο - Google Patents

Παραγωγο αμιδιου και φαρμακο

Info

Publication number
CY1120169T1
CY1120169T1 CY20171101144T CY171101144T CY1120169T1 CY 1120169 T1 CY1120169 T1 CY 1120169T1 CY 20171101144 T CY20171101144 T CY 20171101144T CY 171101144 T CY171101144 T CY 171101144T CY 1120169 T1 CY1120169 T1 CY 1120169T1
Authority
CY
Cyprus
Prior art keywords
present
het
tyrosine kinase
amidium
drug
Prior art date
Application number
CY20171101144T
Other languages
English (en)
Inventor
Tetsuo Asaki
Yukiteru Sugiyama
Jun Segawa
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of CY1120169T1 publication Critical patent/CY1120169T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Η παρούσα εφεύρεση απευθύνεται σ' ένα παράγωγο αμιδίου που διαθέτει εξαιρετική ανασταλτική δράση κινάσης τυροσίνης BCR-ABL, ή ενός άλατος αυτής. Η παρούσα εφεύρεση παρέχει ένα παράγωγο αμιδίου που αντιπροσωπεύεται από τον ακόλουθο γενικό τύπο [1]: (όπου το R 1 αντιπροσωπεύει -CH 2 -R 11, κ.λπ.˙ το R 2 αντιπροσωπεύει αλκυλ, αλογόνο, αλοαλκυλ, κ.λπ.˙ το R 3 αντιπροσωπεύει υδρογόνο, κ.λπ.˙ το Het1 αντιπροσωπεύει μία ομάδα του τύπου [6] όπως παραπάνω, κ.λπ.˙ και το Het2 αντιπροσωπεύει πυριμιδινυλ, κ.λπ.), ή ένα φαρμακευτικώς αποδεκτό άλας αυτής, και μία φαρμακευτική σύνθεση που περιλαμβάνει αυτή ως δραστικό συστατικό. Η ένωση της παρούσας εφεύρεσης είναι χρήσιμη ως ένας αναστολέας κινάσης τυροσίνης BCR-ABL.
CY20171101144T 2003-12-25 2017-11-02 Παραγωγο αμιδιου και φαρμακο CY1120169T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003431398 2003-12-25
PCT/JP2004/019553 WO2005063709A1 (ja) 2003-12-25 2004-12-27 アミド誘導体及び医薬

Publications (1)

Publication Number Publication Date
CY1120169T1 true CY1120169T1 (el) 2018-12-12

Family

ID=34736430

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101144T CY1120169T1 (el) 2003-12-25 2017-11-02 Παραγωγο αμιδιου και φαρμακο

Country Status (19)

Country Link
US (1) US7728131B2 (el)
EP (2) EP1702917B1 (el)
JP (3) JPWO2005063709A1 (el)
KR (1) KR100848067B1 (el)
CN (2) CN101456841B (el)
AU (1) AU2004309248B2 (el)
BR (1) BRPI0418074B8 (el)
CA (1) CA2551529C (el)
CY (1) CY1120169T1 (el)
DK (1) DK1702917T3 (el)
ES (1) ES2651615T3 (el)
HU (1) HUE034712T2 (el)
LT (1) LT1702917T (el)
MX (1) MXPA06007237A (el)
PL (1) PL1702917T3 (el)
PT (1) PT1702917T (el)
RU (1) RU2410375C9 (el)
SI (1) SI1702917T1 (el)
WO (1) WO2005063709A1 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
JP2007297306A (ja) * 2006-04-28 2007-11-15 Kaneka Corp 光学活性３−（１−ピロリジニル）ピロリジンの製造法
US8093259B2 (en) 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
US20100048597A1 (en) * 2006-12-22 2010-02-25 Novartis Ag Organic Compounds and Their Uses
CN101657446B (zh) 2007-02-13 2013-05-15 Ab科学有限公司 合成作为激酶抑制剂的2-氨基噻唑化合物的方法
EP2152079A4 (en) * 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
WO2011008788A1 (en) * 2009-07-14 2011-01-20 Dawei Zhang Fluoro-substituted compounds as kinase inhibitors and methods of use thereof
CN104402860A (zh) * 2010-05-19 2015-03-11 江苏豪森药业股份有限公司 甲磺酸伊马替尼中间体的制备方法
CN102477009B (zh) * 2010-11-23 2014-01-01 清华大学深圳研究生院 取代的（s）-苯甲磺酰基吡咯烷-3-氨基衍生物及其制备方法与应用
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) * 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
FR2980477B1 (fr) * 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
US9695118B2 (en) 2012-04-24 2017-07-04 Chugai Seiyaku Kabushiki Kaisha Benzamide derivative
TW201348213A (zh) 2012-04-24 2013-12-01 Chugai Pharmaceutical Co Ltd 喹唑啉二酮衍生物
TW201605805A (zh) 2013-10-23 2016-02-16 Chugai Pharmaceutical Co Ltd 喹唑啉酮及異喹啉酮衍生物
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
CN104876879B (zh) * 2015-04-14 2018-05-18 中国科学院合肥物质科学研究院 一种bcr-abl激酶抑制剂
CN106187995A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含酰胺键杂环类化合物及其制备方法和应用
WO2016210296A1 (en) * 2015-06-26 2016-12-29 Dana-Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
JP6994715B2 (ja) * 2017-10-04 2022-02-04 国立大学法人京都大学 Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
US20220048893A1 (en) * 2019-03-05 2022-02-17 Hongyi & Associates Llc Compounds for Treating Neurodegenerative Diseases and Cancers
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (el) * 1992-04-03 1994-06-21 Ciba Geigy Ag
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
EP1533304B1 (en) * 2002-06-28 2009-11-04 Nippon Shinyaku Co., Ltd. Amide derivative
IL166528A0 (en) * 2002-08-02 2006-01-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
WO2004096225A2 (en) * 2003-04-28 2004-11-11 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
ATE395052T1 (de) * 2003-08-15 2008-05-15 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes

Also Published As

Publication number Publication date
SI1702917T1 (en) 2018-01-31
EP1702917A4 (en) 2009-06-03
ES2651615T3 (es) 2018-01-29
MXPA06007237A (es) 2006-08-18
BRPI0418074B1 (pt) 2019-06-18
RU2006126974A (ru) 2008-01-27
AU2004309248B2 (en) 2009-11-05
BRPI0418074B8 (pt) 2021-05-25
JP2012121893A (ja) 2012-06-28
PL1702917T3 (pl) 2018-02-28
KR100848067B1 (ko) 2008-07-23
JP2014196291A (ja) 2014-10-16
BRPI0418074A (pt) 2007-04-17
EP1702917A1 (en) 2006-09-20
DK1702917T3 (da) 2017-11-13
RU2410375C2 (ru) 2011-01-27
JPWO2005063709A1 (ja) 2007-07-19
US20080293940A1 (en) 2008-11-27
PT1702917T (pt) 2017-11-14
CA2551529A1 (en) 2005-07-14
CN101456841A (zh) 2009-06-17
AU2004309248A1 (en) 2005-07-14
HUE034712T2 (hu) 2018-02-28
RU2410375C9 (ru) 2017-08-02
CN100526298C (zh) 2009-08-12
CA2551529C (en) 2011-02-01
WO2005063709A1 (ja) 2005-07-14
EP1702917B1 (en) 2017-08-02
EP3299358A1 (en) 2018-03-28
CN101456841B (zh) 2012-01-25
CN1898208A (zh) 2007-01-17
KR20060127901A (ko) 2006-12-13
LT1702917T (lt) 2017-12-11
US7728131B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
CY1120169T1 (el) Παραγωγο αμιδιου και φαρμακο
AU2003246100A1 (en) Amide derivative
MA28076A1 (fr) Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
ME01312B (me) Heteroaril supstituirani pirol0[2,3-b]piridini i pirol0 [ 2,3-b]pirimidini kao inhibitori janus kinaze
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
MY126862A (en) Purine derivatives inhibitors of tyrosine protein kinase syk
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
PT1003725E (pt) Fungicidas de fluoropirazoldifenilamidas
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
BRPI0607214A2 (pt) derivados de 2-(4-cianofenilamino) pirimidina inibidores de hiv
RS53211B (en) PYRIDO [2,3-d] PYRIMIDINE DERIVATIVES, THEIR PRODUCTION, THEIR USE IN THERAPY
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
CY1110898T1 (el) Νεα παραγωγα πυριδινοκαρβοξυλικου οξεος ή αλατα αυτων
ATE325116T1 (de) Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
ATE325809T1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl- amino-5-phenyl-pentansäure
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
CY1113801T1 (el) Παραγωγο κιναζολινης και φαρμακευτικο ειδος
ATE434615T1 (de) Farnesyltransferase hemmende benzoheterocyclische derivate